Pain Therapeutics has had the last word on its four-time reject Remoxy — and it’s a bitter one.
After a meeting with the FDA, the biotech says, “we believe we are no closer today to product approval than we were over a year ago” thanks to “shambolic regulations” at the agency.
Copyright © 2019,